New evidence compares micro-ultrasound and MRI fusion biopsy for detecting clinically significant prostate cancer. Find out ...

Ultra-high-field 5 T MRI improves prostate cancer image quality and diagnostic performance versus 3 T. Learn more about its potential.

One in eight men will develop prostate cancer in their lifetime. Surgery to treat the disease can lead to unwelcome side effects. A minimally invasive alternative that avoids surgery is now available ...

Researchers from Rice University and Vanderbilt University have made significant advancements in the fight against prostate cancer. They have shown that combining a small-molecule therapy called tumor ...

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...

Mercy Medical Center is offering a new, noninvasive treatment option for men with localized prostate cancer using high-intensity focused ultrasound, also known ...

A CUTTING-EDGE cold laser therapy could effectively treat prostate cancer and slash the risk of any debilitating side effects. Australian researchers discovered that the new treatment could ...

Credit: Thinkstock By 5 years, 92% of men recovered pad-free continence, and 87% had preserved erectile function sufficient for penetration. MRI-guided whole-gland transurethral ultrasound ablation ...

New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy MiraDx, a molecular ...

Market OverviewThe global transrectal ultrasound (TRUS) market is experiencing consistent expansion and is projected to grow at a compound annual growth rate of around 6% during the forecast period.

Well demarcated hypoechoic areas in suspicious regions on MRI identify men more likely to have Gleason 7 or higher prostate cancer found on biopsy. Ultrasound characteristics of prostate regions that ...

The 2 groups--those receiving ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy--had similar overall survival, which was 81% and 79%, respectively, at 10 years.